Beneficial hepatic effect of troglitazone in a patient with antimitochondrial antibody-negative primary biliary cirrhosis.
Okai
Takashi
T
Mouri
Hisatsugu
H
Yamaguchi
Yasushi
Y
Nakanuma
Yasuni
Y
Sawabu
Norio
N
D001323:Autoantibodies / Q000276:immunology; D002839:Chromans / Q000008:administration & dosage*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D008105:Liver Cirrhosis, Biliary / Q000150:complications / Q000188:drug therapy* / Q000276:immunology; D008875:Middle Aged; D008928:Mitochondria / Q000276:immunology; D013844:Thiazoles / Q000008:administration & dosage*; D045162:Thiazolidinediones; D016896:Treatment Outcome; D000077288:Troglitazone
D001323:Autoantibodies; D002839:Chromans; D007004:Hypoglycemic Agents; D013844:Thiazoles; D045162:Thiazolidinediones; D000077288:Troglitazone